{"id":53506,"date":"2023-02-01T11:04:41","date_gmt":"2023-02-01T10:04:41","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/"},"modified":"2023-02-01T11:04:41","modified_gmt":"2023-02-01T10:04:41","slug":"scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/","title":{"rendered":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease"},"content":{"rendered":"
\n

\nCRADA combines Scenic Biotech\u2019s genetic modifier platform with NIH\u2019s patient registry to unlock genetic modifiers as a path to novel therapies for<\/i> Niemann-Pick Type C disease<\/i>\n<\/p>\n

AMSTERDAM–(BUSINESS WIRE)–Scenic Biotech<\/a>, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver<\/i> National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to support its therapeutic program for the treatment of Niemann-Pick Type C (NPC) disease, which is a severe, progressive and lethal neurological disorder. The goal of the collaboration is to obtain clinical insights into genes that can reduce the severity of NPC. Under the terms of the CRADA, NICHD will grant Scenic Biotech access to its extensive clinical dataset and whole genome DNA sequence data derived from NPC patients. Forbes D. Porter, MD, PhD, Senior Investigator at NICHD, will be the principal investigator for this study based on his long-running clinical protocols that track the natural history of rare genetic disorders, including NPC.\n<\/p>\n

<\/a><\/p>\n

\n\u201cThe CRADA with the NIH will help advance our work toward identifying genetic modifiers for NPC. Our aim is to develop novel therapeutics that act by suppressing or completely blocking the effect of a disease-causing mutated gene. Through the combined efforts with Dr. Porter\u2019s team, we hope to further enable the discovery of a tailor-made, disease-modifying small molecule therapeutic for this devastating disease,\u201d commented Sebastian Nijman, CSO and co-founder of<\/b> Scenic Biotech<\/b>.\n<\/p>\n

\nAbout Scenic Biotech<\/b>\n<\/p>\n

\nScenic Biotech is at the forefront of identifying genetic modifiers, naturally occurring genes that compensate for mutations responsible for severe diseases. Our robust technologies, reproducible approach and high-resolution insights into disease pathways enable us to develop small-molecule compounds that start with genetic modifiers to provide new therapeutic concepts. By understanding the genome\u2019s power to correct toward health, Scenic Biotech will bring novel therapeutics to patients in need.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please contact:<\/b>\n<\/p>\n

\nScenic Biotech<\/b>
Accolade Izeboud, PhD, CEO
\n
Phone: +31 6 51 06 27 97
\n
Email: Accolade.izeboud@scenicbiotech.com<\/a>\n<\/p>\n

\nTrophic Communications<\/b>
Eva Mulder \/ Desmond James
\n
Phone: +31 6 52 33 15 79 or +49 151 6785 9086
\n
Email: scenic@trophic.eu<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CRADA combines Scenic Biotech\u2019s genetic modifier platform with NIH\u2019s patient registry to unlock genetic modifiers as a path to novel therapies for Niemann-Pick Type C disease AMSTERDAM–(BUSINESS WIRE)–Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative Research and Development … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53506","6":"format-standard","7":"category-industry"},"yoast_head":"\nScenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CRADA combines Scenic Biotech\u2019s genetic modifier platform with NIH\u2019s patient registry to unlock genetic modifiers as a path to novel therapies for Niemann-Pick Type C disease AMSTERDAM–(BUSINESS WIRE)–Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative Research and Development ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-01T10:04:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230201005072\/en\/822873\/21\/LOGO_SB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease\",\"datePublished\":\"2023-02-01T10:04:41+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/\"},\"wordCount\":384,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005072\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/\",\"name\":\"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005072\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\",\"datePublished\":\"2023-02-01T10:04:41+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005072\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230201005072\\\/en\\\/822873\\\/21\\\/LOGO_SB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/","og_locale":"en_US","og_type":"article","og_title":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease - Pharma Trend","og_description":"CRADA combines Scenic Biotech\u2019s genetic modifier platform with NIH\u2019s patient registry to unlock genetic modifiers as a path to novel therapies for Niemann-Pick Type C disease AMSTERDAM–(BUSINESS WIRE)–Scenic Biotech, a pioneer in the discovery of genetic modifiers developing therapeutics to treat severe diseases, today announced that it has entered into a Cooperative Research and Development ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-01T10:04:41+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230201005072\/en\/822873\/21\/LOGO_SB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease","datePublished":"2023-02-01T10:04:41+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/"},"wordCount":384,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005072\/en\/822873\/21\/LOGO_SB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/","url":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/","name":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230201005072\/en\/822873\/21\/LOGO_SB.jpg","datePublished":"2023-02-01T10:04:41+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230201005072\/en\/822873\/21\/LOGO_SB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230201005072\/en\/822873\/21\/LOGO_SB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/scenic-biotech-enters-cooperative-research-development-agreement-with-the-national-institutes-of-health-for-genetic-modifier-based-treatment-approach-for-niemann-pick-type-c-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Scenic Biotech Enters Cooperative Research & Development Agreement with the National Institutes of Health for Genetic Modifier-Based Treatment Approach for Niemann-Pick Type C Disease"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53506"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53506\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}